Aravive is an endocrine-focused biopharmaceutical company that engaged in developing a long-acting form of recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease that affects pediatric and adult patients. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN?. Somavaratan includes a long N-terminal XTEN sequence, XTEN1, which is added to rhGH as a fusion protein, increasing the hydrodynamic size of the rhGH and thereby reducing glomerular filtration. A C-terminal XTEN sequence, XTEN2, is also added to reduce receptor mediated clearance by decreasing receptor binding.
  • TickerARAV
  • ISINUS03890D1081
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ValuEngine Rating and Forecast Report for ARAV

ResearchPool Subscriptions

Get the most out of your insights

Get in touch